Trials / Completed
CompletedNCT00761306
Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
A Long-term, Open-label Study Evaluating the Safety and Tolerability of [Vortioxetine] Lu AA21004 in Patients With Major Depressive Disorder
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 74 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate long-term safety and tolerability of Vortioxetine over a period of 52 weeks in patients with Major Depressive Disorder (MDD) having completed 6-week acute treatment in study NCT00839423 / 11492A.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vortioxetine (Lu AA21004) | 5 or 10 mg/day; tablets; orally |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2008-09-01
- Completion
- 2008-10-01
- First posted
- 2008-09-29
- Last updated
- 2014-01-29
- Results posted
- 2013-12-17
Source: ClinicalTrials.gov record NCT00761306. Inclusion in this directory is not an endorsement.